By Marie Rosenthal, MS
The CDC The CDC recommended a new passive immunization starting this fall to help protect all infants younger than 8 months and some older infants at increased risk for severe illness caused by respiratory syncytial virus (RSV).
CDC Director Mandy Cohen, MD, MPH, adopted the recommendation of the CDC’s Advisory Committee for Immunization Practices (ACIP), which met earlier in the day, for the use of nirsevimab (Beyfortus, AstraZeneca), a long-acting monoclonal